As new data come to be available to inform estimates of TB incidence from 2024 onwards, using these products is usually phased out. qualified prospects the setting of the global research agenda on STIs, such as the event of diagnostic tests, vaccines and additional drugs for gonorrhoea and syphilis. , https://us.hc6.org/